Rhythm BiosciencesFRA:0RY +0.93%31 PB Ratio is 13.63 as of Jun. 26, 2026. GuruFocus rates FRA:0RY with a GF Score™ of 31/100. The stock has 6 warning signs investors should review. Among 196 Medical Diagnostics & Research companies, Rhythm Biosciences ranks worse than 93.88% on this metric.
The historical rank and industry rank for Rhythm Biosciences's PB Ratio or its related term are showing as below:
FRA:0RY'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 18.33
Current: 17.83
During the past 8 years, Rhythm Biosciences's highest PB Ratio was 18.33. The lowest was 0.00. And the median was 0.00.
FRA:0RY's PB Ratio is ranked worse than 93.88% of 196
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.05
vs FRA:0RY: 17.83
During the past 12 months, Rhythm Biosciences's average Book Value Per Share Growth Rate was -64.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -61.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -32.20% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Rhythm Biosciences was 17.60% per year. The lowest was -61.10% per year. And the median was -27.90% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Rhythm Biosciences PB Ratio Related Terms
Rhythm Biosciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Rhythm Biosciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Rhythm Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhythm Biosciences PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Rhythm Biosciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Rhythm Biosciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Rhythm Biosciences (FRA:0RY) has a PB Ratio of 13.63 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Rhythm Biosciences and its competitors. According to the industry distribution chart, Rhythm Biosciences ranks #184 out of 196 companies in the Medical Diagnostics & Research industry, placing it in the top 93.9%.
Is Rhythm Biosciences' PB Ratio too high?
Rhythm Biosciences' current PB Ratio is 13.63. The Medical Diagnostics & Research industry median PB Ratio is 2.05. Rhythm Biosciences' value of 13.63 is 564.9% above this industry median. Based on the distribution chart, Rhythm Biosciences ranks #184 out of 196 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Rhythm Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Biosciences' PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Rhythm Biosciences ranks #184 out of 196 companies for PB Ratio. This places Rhythm Biosciences in the lower half of its industry. The industry median PB Ratio is 2.05. Rhythm Biosciences' value of 13.63 is 564.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.05, based on 196 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rhythm Biosciences's current PB Ratio of 13.63 is 564.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Rhythm Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhythm Biosciences's current PB Ratio is 13.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Biosciences stock overvalued right now?
Rhythm Biosciences (FRA:0RY) has a current PB Ratio of 13.63. The current PB Ratio is 13.63 and 564.9% above the Medical Diagnostics & Research industry median of 2.05. Rhythm Biosciences' overall GF Score™ is 31/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Rhythm Biosciences (FRA:0RY), the current PB Ratio is 13.63 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. The product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.
31GF Score
Get the complete analysis for FRA:0RY
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0RY has been successfully added to your 
